Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

Effective antiviral therapy is essential for achieving sustained virological response (SVR) in hepatitis C virus (HCV)‐infected patients. The phase 2 COSMOS study reported high SVR rates in treatment‐naive and prior null‐responder HCV genotype (GT) 1‐infected patients receiving simeprevir+sofosbuvir...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwo, Paul, Gitlin, Norman, Nahass, Ronald, Bernstein, David, Etzkorn, Kyle, Rojter, Sergio, Schiff, Eugene, Davis, Mitchell, Ruane, Peter, Younes, Ziad, Kalmeijer, Ronald, Sinha, Rekha, Peeters, Monika, Lenz, Oliver, Fevery, Bart, De La Rosa, Guy, Scott, Jane, Witek, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Viral Hepatitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412860/
https://www.ncbi.nlm.nih.gov/pubmed/26799692
http://dx.doi.org/10.1002/hep.28467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412860/
https://www.ncbi.nlm.nih.gov/pubmed/26799692
http://dx.doi.org/10.1002/hep.28467

Ejemplares similares